EP2741750A1 - Pharmaceutical composition comprising cefuroxime - Google Patents
Pharmaceutical composition comprising cefuroximeInfo
- Publication number
- EP2741750A1 EP2741750A1 EP12750614.5A EP12750614A EP2741750A1 EP 2741750 A1 EP2741750 A1 EP 2741750A1 EP 12750614 A EP12750614 A EP 12750614A EP 2741750 A1 EP2741750 A1 EP 2741750A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cefuroxime axetil
- composition
- lipid
- sweetener
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
Definitions
- the common oral dosage form include , liquid mixture like solution, suspension, solid dosage form like tablets , capsules and liquid filled capsules etc.
- patient at extremes of ages such as children and the elderly , often experience difficulty in swallowing solid oral dosage form, for these patients the drug are mostly in liquid dosage form such as solution , suspension and emulsion.
- This dosage form usually lead to perceptible exposure of active ingredients to taste buds and if the active ingredient is bitter this gives extremely unpleasant bitter taste.
- taste masking is major problem when the drug is extremely unpleasant and bitter in taste. This problem is not restricted to liquid oral composition like solution and syrups but is also encountered in oral dry suspension wherein the dosage form usually lead to perceptible exposure of active ingredients to taste buds.
- Cefuroxime axetil In the formulation of Cefuroxime axetil into granules it is important to avoid the release of the drug into any liquid medium in which it is suspended or indeed into the mouth when administering. Such problem may be minimized by formulating the Cefuroxime axetil as lipid coated particles.
- WO 2007/061803 Patent relates to functional sweeteners composition comprising non - caloric or low - caloric natural or synthetic, high potency sweeteners and method of masking and using them.
- This invention discloses in its specification the use of different functional sweetener comprising of atleast one non - caloric or low caloric natural or synthetic, high potency sweetener, at least one sweet taste improving sweetener, and atleast one functional ingredient, such as C - reactive protein reducing substance.
- This invention also includes the method to improve the taste of non - caloric or low caloric high potency sweetener by imparting a more sugar like taste or characteristic.
- the sweetener system used in the composition of present invention prove to be better to overcome the bitter taste, which has been evaluated and results discussed herein below in this application.
- the taste masked composition of present invention comprises a bitter tasting active drug, wherein the active drug used is cefuroxime axetil , a integral coating of lipid which is insoluble in aqueous media and serve to mask the bitter taste of cefuroxime axetil upon oral administration , a "sweetener system" as lipid coating goes up to some extend to provide bitterness inhibition.
- cefuroxime axetil used in the examples was highly pure spray dried amorphous material.
- the Sweetener system was blended together with the cefuroxime axetil granules as a dry mix ensuring that they are evenly in admixture.
- Sweetener system comprises of acesulfame, neotame & along with the third sweetener sucralose was blended together with the cefuroxime axetil lipid coated granules as a dry mix ensuring that they are evenly in admixture.
- Cefuroxime Axetil oral suspension 125mg/5ml
- Sweetener system comprises of neotame, sucralose along with sugar alcohol sorbitol as sweetener was blended together with the cefuroxime axetil lipid coated granules as a dry mix ensuring that they are evenly in admixture.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2275DE2011 | 2011-08-12 | ||
PCT/IB2012/053283 WO2013024373A1 (en) | 2011-08-12 | 2012-06-28 | Pharmaceutical composition comprising cefuroxime |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2741750A1 true EP2741750A1 (en) | 2014-06-18 |
Family
ID=46724550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12750614.5A Withdrawn EP2741750A1 (en) | 2011-08-12 | 2012-06-28 | Pharmaceutical composition comprising cefuroxime |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2741750A1 (en) |
WO (1) | WO2013024373A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103610680B (en) * | 2013-11-07 | 2015-12-30 | 国药集团致君(深圳)制药有限公司 | A kind of CEFUROXIME AXETIL composition and method of making the same |
ES2966816T3 (en) | 2019-02-22 | 2024-04-24 | Catalent Uk Swindon Zydis Ltd | Minimization of agglomeration, aeration and coating preservation of pharmaceutical compositions comprising ibuprofen |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1453049A (en) | 1973-08-21 | 1976-10-20 | Glaxo Lab Ltd | Cephalosporing antibiotics |
YU44680B (en) | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
NL193682C (en) | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Coated Cefuroxime Maxetil Composition. |
WO1994025006A1 (en) | 1993-04-26 | 1994-11-10 | Affinity Biotech, Inc. | Taste-masking pharmaceutical compositions and methods for making the same |
HRP20020924A2 (en) | 2001-11-23 | 2003-10-31 | Glaxo Group Ltd | Pharmaceutical composition |
EP1727524B1 (en) | 2004-03-19 | 2009-10-21 | Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. | Preparation of lipid coated cefuroxime axetil |
US7378109B2 (en) | 2004-12-23 | 2008-05-27 | Council Of Scientific And Industrial Research | Pharmaceutical composition for improving palatability of drugs and process for preparation thereof |
US20070116839A1 (en) | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
-
2012
- 2012-06-28 EP EP12750614.5A patent/EP2741750A1/en not_active Withdrawn
- 2012-06-28 WO PCT/IB2012/053283 patent/WO2013024373A1/en active Search and Examination
Non-Patent Citations (1)
Title |
---|
See references of WO2013024373A1 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
Also Published As
Publication number | Publication date |
---|---|
WO2013024373A1 (en) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2874967B2 (en) | Pharmaceutical water suspension for drug actives essentially insoluble in water | |
EP1370247B1 (en) | Taste masked pharmaceutical compositions | |
EP1194153B1 (en) | Taste masked pharmaceutical liquid formulations | |
KR100979328B1 (en) | Coated particulate cefuroxime axetil compositions | |
JP6092629B2 (en) | Suspension prepared for use with rifaximin | |
WO2003047502A1 (en) | Taste masked aqueous liquid pharmaceutical composition | |
EP2741750A1 (en) | Pharmaceutical composition comprising cefuroxime | |
JP2016532660A (en) | Aprepitant oral liquid formulation | |
EP2313083A1 (en) | Oral compositions of clindamycin | |
KR102413426B1 (en) | Orally disintegrating film comprising naratriptan | |
JP2002536401A (en) | Metamizole-containing foamable pharmaceutical composition | |
JP2002154949A (en) | Solid preparation for internal use | |
WO2024023785A1 (en) | A stable pharmaceutical oral liquid formulation of an antispasmodic agent | |
WO2024023786A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140310 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DHANUKA, MANISH Inventor name: DHOKA, ASHOKA Inventor name: DHOKA, VISHAL, ASHOKA Inventor name: SRIVASTAVA, RAVI, PRATAP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150713 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151124 |